Skip Navigation


Annals of Oncology Advance Access originally published online on April 11, 2007
Annals of Oncology 2007 18(7):1203-1208; doi:10.1093/annonc/mdm094
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/7/1203    most recent
mdm094v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Niitsu, N
Right arrow Articles by Hirano, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niitsu, N
Right arrow Articles by Hirano, M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

hematologic malignancies

Clinicopathologic correlations of stage IE/IIE primary thyroid diffuse large B-cell lymphoma

N Niitsu1,2,*, M Okamoto2, N Nakamura2, H Nakamine2, M Bessho1 and M Hirano2

1 Division of Hematology, Department of Internal Medicine, Saitama Medical University, Saitama, Japan
2 Adult Lymphoma Treatment Study Group (ALTSG), Nagoya, Japan

* Correspondence to: Dr N. Niitsu, Division of Hematology, Department of Internal Medicine, Saitama Medical University, 38 Morohongo, Moroyama, Iruma-Gun, Saitama, Japan. Tel: +81-49-276-1826; Fax: +81-49-276-1826; E-mail: nniitsu{at}saitama-med.ac.jp

Background: We studied the clinicopathological characteristics and prognoses of localized stage thyroid diffuse large B-cell lymphoma (DLBCL).

Patients and methods: This study included 32 patients with stage I/IIE thyroid DLBCL. Their median age was 66 years, the male/female ratio was 10/22.

Results: As to the cellular immunophenotype, CD20 was positive in 31/32, CD5 in 0/32, CD10 in 4/32, CD23 in 1/32, BCL2 in 14/30, and BCL6 in 24/32. Twelve cases showed abnormal karyotypes: two cases with t(8;14)(q24;q32), four cases with 3q27, two cases with 17p11, and four cases with other abnormal karyotypes. As for treatment, eight cases were treated with chemotherapy alone and 24 cases were treated with chemotherapy followed by radiotherapy. Complete response was achieved in 94%. The 5-year progression-free survival was 84% and the 5-year overall survival was 90% with a median follow-up period of 62 months. The germinal center B-cell (GCB) type had a significantly better prognosis than the non-GCB type.

Conclusion: Localized stage thyroid DLBCL is a disease with a relatively good prognosis. It is, however, a heterogeneous disease with regard to histological type and pathological state. Localized stage thyroid DLBCL has a good prognosis and it is that there are more GCB-type DLBCL lymphomas.

Key words: BCL-6, germinal center B cell, Hashimoto's disease, nm23-H1, Thyroid lymphoma

Received for publication January 4, 2007. Revision received February 8, 2007. Accepted for publication February 16, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.